PTHS
Pelthos Therapeutics Inc.21.83
-0.42-1.89%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
67.38MP/E (TTM)
-Basic EPS (TTM)
-18.14Dividend Yield
0%Recent Filings
8-K
$50M venture loan closed
Pelthos Therapeutics closed a $50M senior secured venture loan with Horizon Technology Finance on January 12, 2026, drawing $30M upfront while $20M awaits milestones. Funds fuel ZELSUVMI commercialization, Xepi and Xeglyze launches, yet bind assets as collateral. Debt matures 2031; warrants issued for 65,488 shares at $27.49.
8-K
Director pay aligned with peers
Pelthos Therapeutics boosted non-employee director cash retainers effective January 1, 2026, raising Non-Executive Chairman pay from $50,000 to $60,000 while adding fees for Audit ($7,000 member/$19,000 chair), Compensation ($5,000/$15,000), and Nominating ($4,000/$12,000) committee roles. Board aligned pay with peers after annual review. No equity grants for ongoing service. Policy sharpens director incentives.
8-K
Pelthos acquires Xeglyze assets
Pelthos Therapeutics closed its $1.8M acquisition of Xeglyze, an FDA-approved abametapir topical treatment for head lice, from Hatchtech on December 29, 2025—$450K down payment in November, balance at close. Deal grabs worldwide IP, regulatory filings like NDA 206966, and inventory, with full clawback rights for seller defaults. Pelthos eyes relaunch in H1 2027. Risks hinge on post-close IP transfer.
8-K
Board adds finance expert Einhorn
Pelthos Therapeutics expanded its board from seven to eight directors, appointing finance veteran Andrew J. Einhorn effective December 23, 2025. The 66-year-old joins the Audit and Compensation Committees, bringing four decades in biotech CFO roles and capital markets. He received 12,000 RSUs vesting January 1, 2027. Einhorn bolsters financial expertise for commercial growth.
8-K
Annual meeting results approved
Pelthos Therapeutics held its 2025 Annual Meeting on December 17, electing seven directors including Peter Greenleaf and Richard Baxter with overwhelming support—over 2.2M votes for each. Stockholders approved waiving share issuance limits for senior secured convertible notes and ratified CBIZ CPAs as auditors for fiscal 2025. All passed handily. Directors locked in through 2026.
DNTH
Dianthus Therapeutics, Inc.
41.40-0.52
OMER
Omeros Corporation
8.77-0.43
PTHL
Pheton Holdings Ltd
0.50-0.03
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
RLMD
Relmada Therapeutics, Inc.
4.50+0.14
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02
TENX
Tenax Therapeutics, Inc.
11.16+0.55
TTIPF
-
0.58+0.00
ZEOX
Zeo ScientifiX Inc.
1.99+0.18
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02